Patent assignee · US · COMPANY

Celldex Therapeutics, Inc.

🏢 View company profile →
45Patents
40Active
45Granted
51Portfolio score

Filing activity: May 8, 2001 → Aug 18, 2021 · 6 expiring within 5 years

Most-cited patents

PatentTitleAreaCited byStatus
US9169325B2 Antibodies that bind human CD27 and uses thereof Chemistry; Metallurgy 39 Active
US9259459B2 Antibody vaccine conjugates and uses therefor Emerging Cross-Sectional Technologies 21 Active
US9605081B2 Polynucleotides encoding anti-kit antibodies Physics 10 Active
US7563876B2 Human monoclonal antibodies to dendritic cells Chemistry; Metallurgy 9 Expired
US8236318B2 Antibodies that bind human dendritic and epithelial cell 205 (DEC-205) Chemistry; Metallurgy 8 Active
US10184007B2 Methods of treating a kit-associated cancer by administering anti-kit antibodies Physics 6 Active
US10189907B2 Polynucleotides encoding anti-KIT antibodies Physics 6 Active
US10239943B2 Treatment of eosinophil or mast cell related disorders Chemistry; Metallurgy 6 Active
US8846873B2 Antibodies directed to GPNMB and uses thereof Chemistry; Metallurgy 5 Active
US10633444B2 Agonistic antibodies that bind CD40 Chemistry; Metallurgy 4 Active
US10781267B2 Methods of treating by administering anti-kit antibodies Physics 3 Active
US8362214B2 Antibodies that bind human dendritic and epithelial cell 205 (DEC-205) Chemistry; Metallurgy 3 Active
US8586720B2 Antibodies that bind human dendritic and epithelial cell 205 (DEC-205) Chemistry; Metallurgy 3 Active
US10793639B2 Methods of treating by administering anti-kit antibodies Physics 3 Active
US9649356B2 Method of improving transplant function using soluble complement receptor type I (sCR1) Chemistry; Metallurgy 3 Active
US8664176B2 Treatment for age-related macular degeneration and other diseases of the eye Human Necessities 2 Active
US10774146B2 Treatment of eosinophil or mast cell related disorders Chemistry; Metallurgy 2 Active
US8318165B2 Antibodies against human melanoma-associated chondroitin sulphate proteoglycan (MCSP) Chemistry; Metallurgy 2 Active
US10941201B2 Methods of inducing or enhancing an immune response comprising administering agonistic anti-CD40 antibodies Chemistry; Metallurgy 2 Active
US9649357B2 Treatment of chronic nephropathies using soluble complement receptor type I (sCR1) Human Necessities 1 Active
US10392442B2 Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment Chemistry; Metallurgy 1 Active
US10668152B2 Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment Chemistry; Metallurgy 1 Active
US11332537B2 Anti-CD27 and anti-PD-L1 antibodies and bispecific constructs Chemistry; Metallurgy 1 Active
US10865244B2 Nucleic acids encoding agonistic antibodies that bind CD40 Chemistry; Metallurgy 1 Active
US9295713B2 Treatment of chronic nephropathies using soluble complement receptor type I (sCR1) Human Necessities 1 Active

Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.